| 8.11 0.21 (2.66%) | 09-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.08 | 1-year : | 30.29 |
| Resists | First : | 18.9 | Second : | 25.94 |
| Pivot price | 9.26  |
|||
| Supports | First : | 7.53 | Second : | 6.26 |
| MAs | MA(5) : | 7.9 |
MA(20) : | 12.69 |
| MA(100) : | 22.46 |
MA(250) : | 18.86 |
|
| MACD | MACD : | -4.2 |
Signal : | -4.2 |
| %K %D | K(14,3) : | 5.6 |
D(3) : | 2.6 |
| RSI | RSI(14): 21.7 |
|||
| 52-week | High : | 31.35 | Low : | 3.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALMS ] has closed above bottom band by 25.9%. Bollinger Bands are 37.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.14 - 8.18 | 8.18 - 8.22 |
| Low: | 7.61 - 7.65 | 7.65 - 7.69 |
| Close: | 8.03 - 8.11 | 8.11 - 8.18 |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Wed, 09 Sep 2026
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit - Stock Titan
Tue, 08 Sep 2026
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Thu, 03 Sep 2026
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Wed, 02 Sep 2026
ALMS Stock Slides After IPO Spike As Traders Reset - StocksToTrade
Tue, 01 Sep 2026
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff? - Stocktwits
Tue, 01 Sep 2026
Alumis falls after trial setback for lead drug (ALMS:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 129 (M) |
| Held by Insiders | 1.0439e+008 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 6,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.2145e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 439.8 % |
| Return on Equity (ttm) | -45.4 % |
| Qtrly Rev. Growth | 7.4e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -351 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.83 |
| Dividend | 0 |
| Forward Dividend | 5.85e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|